Amorfix announces retirement of Dr. Philippe Couillard
TSX: AMF
TORONTO, Oct. 3, 2012 /CNW/ - Amorfix Life Sciences Ltd. announced today that Dr. Philippe Couillard has resigned from the Board of Directors and that Dr. Neil Cashman, Amorfix's scientific founder and Chief Scientific Officer, has been appointed as interim Chair.
Dr. Couillard, who previously served as Minister of Health for the Government of Quebec for over 5 years and retired in 2008, has announced his intention to re-enter politics and run for the leadership of the Liberal Party of Quebec. Given these circumstances, Dr. Couillard regrettably will resign from his role as Chairman and member of the Board of Directors of Amorfix. Dr. Couillard joined the Board in September 2009 and has served as chairman since August, 2010. "The Board expresses its profound appreciation to Dr. Couillard for his service to the Company and for his outstanding leadership as the Company redefined itself over the past three years. We wish him much success as he once again enters the field of public service" said Amorfix Director, Dr. Hans Black.
Dr. Couillard said "I would like to thank Dr. Gundel, Dr. Cashman and my other colleagues on the Board of Directors for their support. Amorfix has a very exciting portfolio of novel diagnostics and therapeutic antibodies. I wish the Company future success".
About Amorfix
Amorfix Life Sciences Ltd. (TSX: AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for Alzheimer's disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
This news release contains certain forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it, such as the commitments of potential subscribers that are not binding legal obligations, as well as other factors, that are subject to change. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life Sciences Ltd.
SOURCE: Amorfix Life Sciences Ltd.
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
[email protected]
Janet Clennett
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899
[email protected]
Share this article